Partner at any clinical stage
Technomark partners with life-science companies across Phase I–IV — flexible on the scope and stage of the development programme, and on the structure of the return.
Life-science investment group · Est. London, 1987
Clinical development,
co-funded.
Technomark LS partners with life-science companies to share the cost — and the risk — of Phase I–IV clinical programmes, in exchange for aligned downstream returns.
1987
Founded in London — strategic planning for large pharma
2000
Fund I established — early-stage European life science
8
Portfolio investments — lead or co-lead in every round
7
Companies successfully exited from the Fund I portfolio
2
Offices — London & Philadelphia
Figures as published by Technomark LS, technomarkls.com · retrieved June 2026
The co-development model
Investment that works the way
development actually works.
Share the risk and the cost
Since 2009, the co-funding model has shared the cost of clinical studies directly — investing alongside institutional co-investors, or one-to-one with the company under a co-development agreement.
Earn returns on outcomes
Remuneration is aligned with the programme: equity, downstream royalties and milestone payments — taken only on projects where Technomark’s development and regulatory expertise can make a difference.
“We utilize our global reach to implement innovative strategies for product development and corporate growth.”
Fund I · Established August 2000
A track record written
in acquisitions.
Eight early-stage investments in UK and continental-European life science. Seven exits. In every round, Technomark acted as lead or co-lead investor, structured the investment, and coordinated syndicate building and due diligence.
Portfolio company
Acquired by
Amedis Pharmaceuticals
Takeda
Arakis Ltd.
Sosei
Biovex Limited
Amgen
Matrix Therapeutics
—
Paradigm Therapeutics
Takeda
Proteom Limited
Amura
Ranier Limited
Privately held
SynGenics
Sosei
Portfolio and acquirer history as published by Technomark LS, technomarkls.com/track.html
Heritage
Four decades in life science.
-
1987
Founded in London
Established to provide strategic planning to large pharmaceutical companies — the beginning of the Technomark name in global development.
-
2000
Fund I
A venture capital fund investing in eight early-stage life-science companies — four in drug delivery and med-tech, four therapeutic — across the UK and continental Europe.
-
2009
The co-funding model
A shift from fund structures to sharing the risk and cost of clinical studies directly, in exchange for downstream remuneration.
-
Today
Global co-development
Turn-key clinical development programmes in the US, UK and Europe, and selected regions — delivered through a small, hand-selected network of boutique clinical CROs.
London · Philadelphia
Let’s start working
together.
Technomark invests only in programmes where its development and regulatory expertise can make a difference. If that sounds like your programme, the conversation starts here.
All inquiries — London or Philadelphia office
Ms. Cate Cebass
Global Coordinator
Ccebass@technomarkls.com